Sunday, August 25, 2019

Latest:

‘Please respond:’ Crafting an effective research survey
A new gut-brain connection that keeps weight off (or on) the scale
Throwback Thursday: Football time!
Maintain mental health during hurricane season
Lessons from an old white coat

Baylor College of Medicine Blog Network

Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
PolicyWise
- About PolicyWise
- Follow @BCMEthics on Twitter
Progress Notes
- About Progress Notes
- Connect With Us
bcm.edu

T cells

From The Labs

From the labs to commercialization: Companies merge to implement Baylor College of Medicine-developed therapies for cancer

August 16, 2018August 16, 2018 Ana Rodríguez 0 Comments cancer therapy, commercialization, Marker Therapeutics, Research, T cells, TapImmune, tumor cells

Despite major advances in cancer therapy, conventional cancer treatments continue to be associated with devastating side effects for patients and

From The Labs

A closer look at how elephants fight herpesvirus

April 17, 2018April 27, 2018 Ana Rodríguez 0 Comments Elephant Endotheliotropic Herpesvirus, Houston Zoo, Research, T cells, vaccine candidates

Elephant endotheliotropic herpesvirus (EEHV) affects elephants in the wild and in captivity. It can be latent in adults but in

From The Labs

Mouse blood vessels and immune system can team up against cancer metastasis

May 19, 2017 Ana Rodríguez 0 Comments angiogenesis, anti-blood vessel therapy, Breast Cancer, Breast cancer microenvironment, immunotherapy, Mouse models, T cells, vessel normalization

Picture a shapeless, small mass of tumor cells inside an otherwise healthy organ. The tumor is growing, thanks, among other

From the Labs features the finite nature of brain regeneration. Image courtesy of Dr. Jeannie Chin and Cell Reports.

Listen to the Body of Work Podcast

Body of Work, the Baylor College of Medicine podcast, is an exploration of health topics in the news and important scientific matters featuring insights from experts at Baylor. Listen on your preferred platform.